Please wait while the formulary information is being retrieved.
DRUG IMAGES
ISENTRESS 400 MG TABLET
ISENTRESS 100 MG POWDER PACKET
ISENTRESS 100 MG TABLET CHEW
The following indications for ISENTRESS (raltegravir potassium) have been approved by the FDA:
Indications:
HIV infection
Professional Synonyms:
Human immunodeficiency virus disease
Human immunodeficiency virus infection
Indications:
HIV infection
Professional Synonyms:
Human immunodeficiency virus disease
Human immunodeficiency virus infection
The following dosing information is available for ISENTRESS (raltegravir potassium):
Raltegravir chewable tablets, film-coated tablets, and powder for oral suspension contain raltegravir potassium; dosage is expressed in terms of raltegravir.
Because the formulations have different pharmacokinetic profiles, raltegravir chewable tablets and oral suspension are not bioequivalent to raltegravir film-coated tablets. Do not substitute the chewable tablets or oral suspension for the 400- or 600-mg film-coated tablets.
Because the formulations have different pharmacokinetic profiles, raltegravir chewable tablets and oral suspension are not bioequivalent to raltegravir film-coated tablets. Do not substitute the chewable tablets or oral suspension for the 400- or 600-mg film-coated tablets.
Raltegravir potassium is available for oral administration as 400-mg and 600-mg (Isentress(R) HD) film-coated tablets, 25-mg and 100-mg chewable tablets, and a 100-mg powder for oral suspension. Raltegravir is administered orally once or twice daily without regard to food. Use the drug in conjunction with other antiretrovirals.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| ISENTRESS 400 MG TABLET | Maintenance | Adults take 1 tablet (400 mg) by oral route 2 times per day |
No generic dosing information available.
The following drug interaction information is available for ISENTRESS (raltegravir potassium):
There are 0 contraindications.
There are 7 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Raltegravir/Aluminum & Magnesium Antacids & Magnesium Supplements SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Aluminum and/or magnesium containing antacids may alter raltegravir absorption by altering gastric pH. Magnesium antacids and supplements may bind to raltegravir in the GI tract, preventing its absorption.(1) CLINICAL EFFECTS: Aluminum and/or magnesium containing antacids and magnesium supplements may reduce levels and clinical effectiveness of raltegravir.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Concurrent use of any formulation of raltegravir and aluminum and/or magnesium antacids is not recommended. Instruct patients not to use aluminum and/or magnesium containing antacids or magnesium supplements. Calcium carbonate may be used in place of aluminum and/or magnesium containing antacids in patients receiving raltegravir chewable tablets, oral suspension, or 400 mg tablets. Calcium carbonate is not recommended for patients receiving one daily raltegravir (600 mg tablets).(1) DISCUSSION: Simultaneous administration of aluminum and magnesium hydroxide (20 ml) with raltegravir (400 mg BID) decreased raltegravir maximum concentration (Cmax), area-under-curve (AUC), and minimum concentration (Cmin) by 44%, 49%, and 63%, respectively.(1) Administration of aluminum and magnesium hydroxide (20 ml) 2 hours before raltegravir (400 mg BID) decreased raltegravir Cmax, AUC, and Cmin by 51%, 51%, and 56%, respectively.(1) Administration of aluminum and magnesium hydroxide (20 ml) 2 hours after raltegravir (400 mg BID) decreased raltegravir Cmax, AUC, and Cmin by 22%, 30%, and 57%, respectively.(1) Administration of aluminum and magnesium hydroxide (20 ml) 4 hours before after raltegravir (400 mg BID) decreased raltegravir Cmax, AUC, and Cmin by 22%, 19%, and 60%, respectively.(1) Administration of aluminum and magnesium hydroxide (20 ml) 4 hours after after raltegravir (400 mg BID) decreased raltegravir Cmax, AUC, and Cmin by 30%, 32%, and 62%, respectively.(1) Administration of aluminum and magnesium hydroxide (20 ml) 6 hours before after raltegravir (400 mg BID) decreased raltegravir Cmax, AUC, and Cmin by 10%, 13%, and 50%, respectively.(1) Administration of aluminum and magnesium hydroxide (20 ml) 6 hours after after raltegravir (400 mg BID) decreased raltegravir Cmax, AUC, and Cmin by 10%, 11%, and 49%, respectively.(1) Administration of aluminum and magnesium hydroxide (20 ml) 12 hours after after raltegravir (1200 mg single dose) decreased raltegravir Cmax, AUC, and Cmin by 14%, 14%, and 58%, respectively.(1,2) Data from in vitro(3) and in vivo simulations(4) suggest that magnesium's effect on raltegravir may involve chelation as well as changes in pH. |
ALUMINUM HYDROXIDE, MAGNESIUM CHLORIDE |
| Raltegravir/Rifapentine SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Rifapentine may induce the metabolism of raltegravir by UDP-glucuronosyltransferase 1A1 (UGT1A1).(1) CLINICAL EFFECTS: Concurrent use of once-daily rifapentine may reduce levels and clinical effectiveness of raltegravir.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The concurrent use of once-daily rifapentine is not recommended. Once-weekly rifapentine may be used concurrently at standard doses.(2) DISCUSSION: Concurrent use of rifapentine 600 mg once daily decreased raltegravir minimum concentration (Cmin) by 41%.(2) Concurrent use of rifapentine 900 mg once weekly increased raltegravir area-under-curve (AUC) by 71% and decreased Cmin 12%.(2) |
PRIFTIN |
| Raltegravir/Selected UGT1A1 Inducers SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Strong inducers of UDP-glucuronosyltransferase 1A1 (UGT1A1) may induce the metabolism of raltegravir.(1) CLINICAL EFFECTS: Concurrent use of carbamazepine, fosphenytoin, phenobarbital, phenytoin, or primidone may result in decreased levels and effectiveness of raltegravir.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of raltegravir(1) and Department of Health and Human Services HIV guidelines(2) state that the concurrent use of carbamazepine, fosphenytoin, phenobarbital, phenytoin, or primidone with raltegravir is not recommended. The European AIDS Clinical Society HIV guidelines state that additional monitoring or dose adjustment is likely to be required if these agents are used concurrently.(3) DISCUSSION: Concurrent rifampin (600 mg daily) with raltegravir (400 mg single dose) decreased raltegravir maximum concentration (Cmax), area-under-curve (AUC), and minimum concentration (Cmin) by 38%, 40%, and 61%, respectively. When raltegravir was given at a dosage of 800 mg twice daily with rifampin (600 mg daily), the Cmax and AUC of raltegravir were increased 62% and 27%, respectively, and the Cmin was decreased 53% when compared to the administration of raltegravir (400 mg twice daily) alone.(1,4) Strong inducers of UGT1A1, such as carbamazepine, fosphenytoin, phenobarbital, phenytoin, and primidone are expected to produce similar results.(1,2) |
CARBAMAZEPINE, CARBAMAZEPINE ER, CARBATROL, CEREBYX, DILANTIN, DILANTIN-125, DONNATAL, EPITOL, EQUETRO, FOSPHENYTOIN SODIUM, MYSOLINE, PHENOBARBITAL, PHENOBARBITAL SODIUM, PHENOBARBITAL-BELLADONNA, PHENOBARBITAL-HYOSC-ATROP-SCOP, PHENOHYTRO, PHENYTEK, PHENYTOIN, PHENYTOIN SODIUM, PHENYTOIN SODIUM EXTENDED, PRIMIDONE, SEZABY, TEGRETOL, TEGRETOL XR |
| Betibeglogene Autotemcel/Anti-Retrovirals; Hydroxyurea SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Betibeglogene autotemcel is prepared from apheresed cells that are transduced with a replication defective, self-inactivating lentiviral vector. Antiretrovirals may interfere with the manufacturing of apheresed cells. Hydroxyurea may interfere with hematopoietic stem cell (HSC) mobilization of CD34+ cells.(1) CLINICAL EFFECTS: Use of hydroxyurea before mobilization may result in unsuccessful stem cell mobilization. Use of antiretrovirals before mobilization and apheresis may interfere with the production of betibeglogene autotemcel. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Discontinue antiretrovirals and hydroxyurea for at least one month prior to mobilization and until all cycles of apheresis are completed. If a patient requires antiretrovirals for HIV prophylaxis, then confirm a negative HIV test before beginning mobilization and apheresis of CD34+ cells. DISCUSSION: Antiretroviral medications and hydroxyurea may interfere with the manufacturing of betibeglogene autotemcel therapy.(1) |
ZYNTEGLO |
| Elivaldogene Autotemcel/Anti-Retrovirals SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Elivaldogene autotemcel is prepared from apheresed cells that are transduced with a replication defective, self-inactivating lentiviral vector. Antiretrovirals may interfere with the manufacturing of apheresed cells. CLINICAL EFFECTS: Use of antiretrovirals before mobilization and apheresis may interfere with the production of elivaldogene autotemcel. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Discontinue antiretrovirals for at least one month prior to mobilization and until all cycles of apheresis are completed. If a patient requires antiretrovirals for HIV prophylaxis, then confirm a negative HIV test before beginning mobilization and apheresis of CD34+ cells. DISCUSSION: Antiretroviral medications may interfere with the manufacturing of elivaldogene autotemcel therapy.(1) |
SKYSONA |
| Lovotibeglogene Autotemcel/Anti-Retrovirals SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Lovotibeglogene autotemcel is prepared from apheresed cells that are transduced with a replication defective, self-inactivating lentiviral vector. Antiretrovirals may interfere with the manufacturing of apheresed cells. CLINICAL EFFECTS: Use of antiretrovirals before mobilization and apheresis may interfere with the production of lovotibeglogene autotemcel.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Discontinue antiretrovirals for at least one month prior to mobilization and until all cycles of apheresis are completed.(1) There are some long-acting antiretroviral medications that may require a longer duration of discontinuation for elimination of the medication. If a patient is taking anti-retrovirals for HIV prophylaxis, confirm a negative test for HIV before beginning mobilization and apheresis of CD34+ cells.(1) DISCUSSION: Antiretroviral medications may interfere with the manufacturing of lovotibeglogene autotemcel therapy.(1) |
LYFGENIA |
| Atidarsagene Autotemcel/Anti-Retrovirals SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Atidarsagene autotemcel is prepared from apheresed cells that are transduced with a replication defective, self-inactivating lentiviral vector. Antiretrovirals may interfere with the manufacturing of apheresed cells. CLINICAL EFFECTS: Use of antiretrovirals before mobilization and apheresis may interfere with the production of atidarsagene autotemcel. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Discontinue antiretrovirals for at least one month prior to mobilization (or the expected duration of time needed for elimination of the medication) until all cycles of apheresis are completed. If a patient requires antiretrovirals for HIV prophylaxis, then confirm a negative HIV test before beginning mobilization and apheresis of CD34+ cells. DISCUSSION: Antiretroviral medications may interfere with the manufacturing of atidarsagene autotemcel therapy.(1) |
LENMELDY |
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Raltegravir/Rifampin SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Rifampin may induce the metabolism of raltegravir by UDP-glucuronosyltransferase 1A1 (UGT-1A1).(1-4) CLINICAL EFFECTS: Concurrent use of rifampin may reduce levels and clinical effectiveness of raltegravir.(1-4) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The concurrent use of rifampin and raltegravir should be approached with caution.(1,2) The US manufacturer of raltegravir recommends a dosage of 800 mg raltegravir twice daily with or without food in adult patients receiving concurrent rifampin.(2) The UK manufacturer recommends considering this dosage adjustment as well if concurrent use of rifampin is unavoidable.(4) No dosage adjustment recommendation is available for patients younger than 18 years of age.(1) DISCUSSION: Concurrent rifampin (600 mg daily) with raltegravir (400 mg single dose) decreased raltegravir maximum concentration (Cmax), area-under-curve (AUC), and minimum concentration (Cmin) by 38%, 40%, and 61%, respectively.(1-4) When raltegravir was given at a dosage of 800 mg twice daily with rifampin (600 mg daily), the Cmax and AUC of raltegravir were increased 62% and 27%, respectively, and the Cmin was decreased 53% when compared to the administration of raltegravir (400 mg twice daily) alone.(2) |
RIFADIN, RIFAMPIN |
The following contraindication information is available for ISENTRESS (raltegravir potassium):
Drug contraindication overview.
*None.
*None.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Lactation |
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Rhabdomyolysis |
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Myopathy |
The following adverse reaction information is available for ISENTRESS (raltegravir potassium):
Adverse reaction overview.
Adverse effects reported in 2% or more of patients receiving raltegravir in conjunction with other antiretrovirals include insomnia, headache, dizziness, nausea, and fatigue. Creatine kinase elevations, myopathy, and rhabdomyolysis have been reported.
Adverse effects reported in 2% or more of patients receiving raltegravir in conjunction with other antiretrovirals include insomnia, headache, dizziness, nausea, and fatigue. Creatine kinase elevations, myopathy, and rhabdomyolysis have been reported.
There are 20 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Herpes simplex infection Herpes zoster |
| Rare/Very Rare |
|---|
|
Abnormal hepatic function tests Angioedema Eosinophilia Gastritis Graves' disease Guillain-barre syndrome Hepatic failure Hepatitis Hypersensitivity drug reaction Kidney stone Myopathy Polymyositis Renal failure Rhabdomyolysis Stevens-johnson syndrome Suicidal ideation Thrombocytopenic disorder Toxic epidermal necrolysis |
There are 18 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Dizziness Fatigue Headache disorder Insomnia Nausea |
Acute abdominal pain Dyspepsia Fever General weakness Vomiting |
| Rare/Very Rare |
|---|
|
Ataxia Conjunctivitis Depression Diarrhea Malaise Paranoid disorder Skin rash Symptoms of anxiety |
The following precautions are available for ISENTRESS (raltegravir potassium):
Raltegravir (Isentress(R); 400-mg film-coated tablets) is indicated for use in pediatric patients weighing 2 kg or more and is not recommended in preterm neonates or pediatric patients weighing less than 2 kg. Raltegravir (Isentress(R)HD; 600-mg film-coated tablets) is indicated for use in pediatric patients weighing 40 kg or more. Although this formulation has not been studied in pediatric patients, the manufacturer states that population pharmacokinetic modeling and simulation support the use of the once-daily regimen (two 600-mg film-coated tablets once daily) in those weighing 40 kg or more.
Safety and pharmacokinetics of raltegravir for oral suspension were evaluated in 42 full-term HIV-1 exposed neonates at high risk of acquiring HIV-1 infection in a phase 1, open-label, multicenter, clinical trial (IMPAACT P1110). The safety profile of the drug in these neonates was comparable to that observed in adults receiving the drug. Safety, efficacy, and pharmacokinetics of twice-daily raltegravir were evaluated in HIV-1 infected pediatric patients 4 weeks to 18 years of age in an open-label, multicenter, clinical trial (IMPAACT P1066). The safety profile of the drug in these pediatric patients was comparable to that observed in adults receiving the drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Safety and pharmacokinetics of raltegravir for oral suspension were evaluated in 42 full-term HIV-1 exposed neonates at high risk of acquiring HIV-1 infection in a phase 1, open-label, multicenter, clinical trial (IMPAACT P1110). The safety profile of the drug in these neonates was comparable to that observed in adults receiving the drug. Safety, efficacy, and pharmacokinetics of twice-daily raltegravir were evaluated in HIV-1 infected pediatric patients 4 weeks to 18 years of age in an open-label, multicenter, clinical trial (IMPAACT P1066). The safety profile of the drug in these pediatric patients was comparable to that observed in adults receiving the drug.
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
The Antiretroviral Pregnancy Registry (APR) monitors pregnancy outcomes in females. Healthcare providers should register patients at 800-258-4263. Available data from the APR show no difference in the rate of overall birth defects in infants of pregnant females receiving raltegravir compared with the background rate of major birth defects of 2.7%
in the US reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). Based on prospective reports from the APR of over 850 exposures to raltegravir during pregnancy resulting in live births (including over 450 exposures in the first trimester), the prevalence of defects in live births was 3.1% following first trimester exposure to raltegravir-containing regimens and 3.7%
following second and third trimester exposure to raltegravir-containing regimens. In animal reproduction studies (rats and rabbits), there was no evidence of adverse developmental outcomes when raltegravir was given orally during organogenesis at doses producing exposures approximately 4 times those reported with the maximum recommended human dose of 1.2 g.
In animal studies, raltegravir has been shown to cross the placenta with fetal plasma concentrations 1.5-2.5 times greater than in maternal plasma in rats and 2% of maternal plasma concentrations in rabbits on gestation day 20.
There are limited data on the use of raltegravir 1.2 g (two 600-mg film-coated tablets) once daily in pregnant females.
in the US reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). Based on prospective reports from the APR of over 850 exposures to raltegravir during pregnancy resulting in live births (including over 450 exposures in the first trimester), the prevalence of defects in live births was 3.1% following first trimester exposure to raltegravir-containing regimens and 3.7%
following second and third trimester exposure to raltegravir-containing regimens. In animal reproduction studies (rats and rabbits), there was no evidence of adverse developmental outcomes when raltegravir was given orally during organogenesis at doses producing exposures approximately 4 times those reported with the maximum recommended human dose of 1.2 g.
In animal studies, raltegravir has been shown to cross the placenta with fetal plasma concentrations 1.5-2.5 times greater than in maternal plasma in rats and 2% of maternal plasma concentrations in rabbits on gestation day 20.
There are limited data on the use of raltegravir 1.2 g (two 600-mg film-coated tablets) once daily in pregnant females.
There are no data available regarding the presence of raltegravir in human milk, the effects on the breastfed infant, or the effects on milk production. The drug is distributed into milk in rats; milk concentrations approximately 3 times higher than maternal plasma concentrations were reported at 2 hours after a dose on lactation day 14 in rats receiving oral raltegravir from gestation day 6 to lactation day 14. The HHS perinatal HIV transmission guideline provides updated recommendations on infant feeding.
The guideline states that patients with HIV should receive evidence-based, patient-centered counseling to support shared decision making about infant feeding. During counseling, patients should be informed that feeding with appropriate formula or pasteurized donor human milk from a milk bank eliminates the risk of postnatal HIV transmission to the infant. Additionally, achieving and maintaining viral suppression with antiretroviral therapy during pregnancy and postpartum reduces the risk of breastfeeding HIV transmission to <1%, but does not completely eliminate the risk. Replacement feeding with formula or banked pasteurized donor milk is recommended when patients with HIV are not on antiretroviral therapy and/or do not have a suppressed viral load during pregnancy (at a minimum throughout the third trimester), as well as at delivery.
The guideline states that patients with HIV should receive evidence-based, patient-centered counseling to support shared decision making about infant feeding. During counseling, patients should be informed that feeding with appropriate formula or pasteurized donor human milk from a milk bank eliminates the risk of postnatal HIV transmission to the infant. Additionally, achieving and maintaining viral suppression with antiretroviral therapy during pregnancy and postpartum reduces the risk of breastfeeding HIV transmission to <1%, but does not completely eliminate the risk. Replacement feeding with formula or banked pasteurized donor milk is recommended when patients with HIV are not on antiretroviral therapy and/or do not have a suppressed viral load during pregnancy (at a minimum throughout the third trimester), as well as at delivery.
The manufacturer makes no specific dosage recommendations for raltegravir in geriatric patients, but recommends careful dosage selection because of possible age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy. Experience in adults 65 years of age and older is insufficient to determine whether they respond differently to raltegravir than younger adults. Reported clinical experience has not identified differences in response between elderly and younger subjects. Raltegravir should be used with caution in geriatric patients because of age-related decreases in hepatic, renal, and/or cardiac function and potential for concomitant disease and drug therapy.
The following prioritized warning is available for ISENTRESS (raltegravir potassium):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ISENTRESS (raltegravir potassium)'s list of indications:
| HIV infection | |
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
Formulary Reference Tool